| Ticker: | TLX |
| Current Price: | $9.23 |
| % Daily Change: | -1.39% |
| Volume (1,000s): | 110.83 |
| Average Volume (1,000s): | 166.20 |
| Market Cap (M): | $3,136.21 |
| 1/2/2024 Price: | $23.84 |
| Change Since Inception: | -61.28% |
Telix Pharmaceuticals Limited
55 Flemington Road
Level 4
North Melbourne, VIC 3051
Australia
Telix Pharmaceuticals develops and commercializes therapeutic and diagnostic radiopharmaceuticals. The company manages three distinct segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. It operates globally with a presence in Australia, Belgium, Canada, the United Kingdom, and the United States.
TLX591 serves as the company’s lead therapeutic candidate. This lutetium-labeled radio antibody-drug conjugate is currently in Phase 3 clinical trials for advanced prostate cancer. Telix also provides Illuccix and Gozellix for prostate cancer treatment. Other key programs include TLX250 for metastatic kidney cancer and TLX101 for glioblastoma. The company also develops TLX66 to condition bone marrow for stem cell transplants.
Telix Pharmaceuticals uses its proprietary RADmAb technology to develop TLX592 for prostate cancer. Their pipeline also includes TLX252 for kidney cancer and TLX400 for bladder tumors. Researchers are testing TLX102 for glioblastoma and multiple myeloma. Additionally, Telix works on TLX300 for soft tissue sarcoma and TLX090 for bone pain management.
Diagnostic innovation remains a priority for the firm. Telix is currently conducting Phase 3 trials for BiPASS to diagnose prostate cancer. The company also produces PET imaging solutions such as AlFluor, TLX250-Px, and TLX101-Px. Founded in 2015, Telix maintains its global headquarters in North Melbourne, Australia.